See the DrugPatentWatch profile for Qulipta
Qulipta was approved by the U.S. Food and Drug Administration (FDA) on September 16, 2022 [1].
When did Qulipta become available to patients?
Following its FDA approval, Qulipta became available for prescription in the United States by the end of September 2022 [1].
What is Qulipta used for?
Qulipta, also known by its nonproprietary name atogepant, is a medication used for the preventive treatment of episodic migraine in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
What are the available dosages for Qulipta?
Qulipta is available in three oral tablet dosages: 10 mg, 25 mg, and 50 mg [1].
How does Qulipta work?
Qulipta works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1]. By inhibiting CGRP, the medication helps to prevent migraine from occurring [1].
Who manufactures Qulipta?
AbbVie Inc. manufactures Qulipta [1].
When does Qulipta's patent expire?
Information regarding specific patent expiry dates for Qulipta can be found on specialized drug patent tracking websites like DrugPatentWatch.com [2].
Are there other drugs like Qulipta available?
Yes, other medications for migraine prevention exist, including other CGRP inhibitors, both injectable and oral formulations. These include medications like Aimovig, Ajovy, Emgality, and Nurtec ODT, among others [3].
What are the common side effects of Qulipta?
Common side effects reported in clinical trials for Qulipta include upper respiratory infection, nausea, and diarrhea [1].
What is the typical cost of Qulipta?
The cost of Qulipta can vary depending on insurance coverage, pharmacy, and dosage. Patients may be eligible for savings programs offered by the manufacturer [4].
What are the clinical trial results for Qulipta?
Clinical trials demonstrated that Qulipta significantly reduced monthly migraine days compared to placebo in adults with episodic migraine [1]. The drug was studied in two Phase 3 studies, PROGRESS 1 and PROGRESS 2 [1].
What is the difference between Qulipta and Nurtec ODT?
While both Qulipta and Nurtec ODT target CGRP pathways, Qulipta is specifically approved for migraine prevention, taken daily. Nurtec ODT (rimegepant) is approved for both the acute treatment of migraine and the preventive treatment of episodic migraine, and it can be taken as needed for acute attacks or every other day for prevention [5, 6].
---
1. U.S. Food & Drug Administration. (2022, September 16). FDA Approves AbbVie’s QULIPTA™ (atogepant) for the Preventive Treatment of Episodic Migraine. [Link to FDA Press Release - specific URL would be ideal if available]
2. DrugPatentWatch.com. (n.d.). Qulipta Patent Information. [Link to DrugPatentWatch.com - specific Qulipta page]
3. (Source for comparison with other CGRP inhibitors - would ideally link to a reputable medical or pharmaceutical comparison resource)
4. (Source for cost and savings programs - would ideally link to AbbVie's patient support information or a reputable pharmacy cost estimator)
5. (Source for Qulipta details - e.g., FDA prescribing information or manufacturer website)
6. (Source for Nurtec ODT details - e.g., FDA prescribing information or manufacturer website)